These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30453344)

  • 21. Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.
    Adamski P; Ostrowska M; Sikora J; Obońska K; Buszko K; Krintus M; Sypniewska G; Marszałł MP; Koziński M; Kubica J
    BMJ Open; 2017 Apr; 7(4):e013218. PubMed ID: 28446521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
    Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
    Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
    Monitillo F; Iacoviello M; Caldarola P; Valle R; Chiatto M; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):977-93. PubMed ID: 25882759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.
    Adamski P; Sikora J; Laskowska E; Buszko K; Ostrowska M; Umińska JM; Sikora A; Skibińska N; Sobczak P; Adamska U; Rość D; Kubica A; Paciorek P; Marszałł MP; Navarese EP; Gorog DA; Kubica J
    PLoS One; 2017; 12(10):e0186013. PubMed ID: 29023473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
    Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
    Brice AE; Hernandez GA; Sanchez M; Haynick M; Mendoza CE
    Platelets; 2017 May; 28(3):305-309. PubMed ID: 27778525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
    Waksman R; Maya J; Angiolillo DJ; Carlson GF; Teng R; Caplan RJ; Ferdinand KC
    Circ Cardiovasc Interv; 2015 Jul; 8(7):e002232. PubMed ID: 26152562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes.
    Li J; Tang W; Storey RF; Husted S; Teng R
    Int J Clin Pharmacol Ther; 2016 Sep; 54(9):666-74. PubMed ID: 27191766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
    Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients.
    Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Bellomo G; Suryapranata H; De Luca G;
    Thromb Res; 2016 Jul; 143():45-9. PubMed ID: 27179132
    [No Abstract]   [Full Text] [Related]  

  • 33. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Parodi G; Bellandi B; Xanthopoulou I; Capranzano P; Capodanno D; Valenti R; Stavrou K; Migliorini A; Antoniucci D; Tamburino C; Alexopoulos D
    Circ Cardiovasc Interv; 2015 Jan; 8(1):. PubMed ID: 25552565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study.
    Laine M; Gaubert M; Frère C; Peyrol M; Thuny F; Yvorra S; Chelini V; Bultez B; Luigi S; Mokrani Z; Bessereau J; Toesca R; Champenois A; Dignat-George F; Paganelli F; Bonello L
    Platelets; 2015; 26(6):570-2. PubMed ID: 25275609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
    Storey RF; Angiolillo DJ; Bonaca MP; Thomas MR; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2016 Mar; 67(10):1145-1154. PubMed ID: 26965534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of the platelet inhibitory effect of the P2Y
    Schoener L; Jellinghaus S; Richter B; Pfluecke C; Ende G; Christoph M; Quick S; Loehn T; Speiser U; Poitz DM; Mierke J; Strasser RH; Ibrahim K
    Clin Res Cardiol; 2017 Nov; 106(11):868-874. PubMed ID: 28653184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ticagrelor.
    Kabil MF; Abo Dena AS; El-Sherbiny IM
    Profiles Drug Subst Excip Relat Methodol; 2022; 47():91-111. PubMed ID: 35396017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
    Coleman CI; Limone BL
    Thromb Haemost; 2014 Jan; 111(1):103-10. PubMed ID: 24136466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.
    Li P; Yang Y; Chen T; Liu Y; Cao A; Liu J; Wang Z; Zhao X; Qin Y; Ma L
    Sci Rep; 2015 Sep; 5():13789. PubMed ID: 26350388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.